Trifork Group AG
32/2025・Trifork Group: Weekly report on share buyback
32/2025・Trifork Group: Weekly report on share buyback
Company announcement no. 32 / 2025
Schindellegi, Switzerland – 30 May 2025
Trifork Group: Weekly report on share buyback
On 28 February 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. For details, please see company announcement no. 7 of 28 February 2025.
Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share capital. Under the program, the following transactions have been made:
Number of shares | Average purchase price (DKK) | Transaction value (DKK) | |
Total beginning | 94,974 | 87.06 | 8,268,765 |
26 May 2025 | 1,300 | 92.08 | 119,704 |
27 May 2025 | 1,400 | 91.90 | 128,660 |
28 May 2025 | 1,400 | 92.31 | 129,234 |
29 May 2025 | Market closed | ||
30 May 2025 | Market closed | ||
Accumulated | 99,074 | 87.27 | 8,646,363 |
A detailed overview of the daily transactions can be found here: https://investor.trifork.com/trifork-shares/
Since the share buyback program was started on 4 March 2025, the total number of repurchased shares is 99,074 at a total amount of DKK 8,646,363.
On 25 March, 25 April and 23 May 2025, 4,370 shares acquired through the share buyback program were utilized for the Executive Management’s monthly fixed salary, representing a change from cash payment to payment partly in shares (refer to company announcement no. 1 of 21 January 2025). On 1 April 2025, 19,943 shares acquired through the share buyback program were utilized to serve the RSU plan of Executive Management and certain employees.
With the transactions stated above, Trifork holds a total of 331,090 treasury shares, corresponding to 1.7%. The total number of registered shares in Trifork is 19,744,899. Adjusted for treasury shares, the number of outstanding shares is 19,413,809.
Investor and media contact
Frederik Svanholm, Group Investment Director, frsv@trifork.com, +41 79 357 73 17
About Trifork
Trifork (Nasdaq Copenhagen: TRIFOR) is a pioneering global technology company, empowering enterprise and public sector customers with innovative digital products and solutions. With 1,215 professionals across 71 business units in 16 countries, Trifork specialises in designing, building, and operating advanced software across sectors such as public administration, healthcare, manufacturing, logistics, energy, financial services, retail, and real estate. The Group’s R&D arm, Trifork Labs, drives innovation by investing in and developing synergistic, high-potential technology companies. Learn more at trifork.com.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Ipsen Pharma31.5.2025 14:00:00 CEST | Press release
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
WithSecure Oyj31.5.2025 08:45:00 CEST | Press release
WithSecure has completed the transaction of Cyber security consulting divestment to Neqst
Teva Pharmaceutical Industries Ltd31.5.2025 03:05:00 CEST | Press release
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
Teva Pharmaceutical Industries Ltd31.5.2025 03:00:00 CEST | Press release
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
Atlantic Petroleum P/F30.5.2025 20:08:23 CEST | Press release
Atlantic Petroleum – Condensed Consolidated Interim Report – 1st Quarter 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom